Advancing CAR T-Cell Therapy for Solid Tumors: Lessons Learned from Lymphoma Treatment

Chimeric antigen receptor (CAR) immunotherapy is one of the most promising modern approaches for the treatment of cancer. To date only two CAR T-cell products, Kymriah(®) and Yescarta(®), have been approved by the Food and Drug Administration (FDA) for the treatment of lymphoblastic leukemia and B-c...

Descripción completa

Detalles Bibliográficos
Autores principales: Titov, Aleksei, Valiullina, Aygul, Zmievskaya, Ekaterina, Zaikova, Ekaterina, Petukhov, Alexey, Miftakhova, Regina, Bulatov, Emil, Rizvanov, Albert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016531/
https://www.ncbi.nlm.nih.gov/pubmed/31947775
http://dx.doi.org/10.3390/cancers12010125

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016531/
https://www.ncbi.nlm.nih.gov/pubmed/31947775
http://dx.doi.org/10.3390/cancers12010125

Ejemplares similares